TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07790861: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbi

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 192 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,220,272

Rescue Site Savings

+$7,401,608

Unlock Full NCT07790861 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07790861 Rescue Dossier →